S
Simona Buccheri
Researcher at University of Palermo
Publications - 26
Citations - 1686
Simona Buccheri is an academic researcher from University of Palermo. The author has contributed to research in topics: Cytotoxic T cell & Cancer. The author has an hindex of 15, co-authored 26 publications receiving 1457 citations. Previous affiliations of Simona Buccheri include ISMETT.
Papers
More filters
Journal ArticleDOI
Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer
Francesco Dieli,David Vermijlen,Fabio Fulfaro,Nadia Caccamo,Serena Meraviglia,Giuseppe Cicero,Andrew Roberts,Simona Buccheri,M. D'Asaro,Nicola Gebbia,Alfredo Salerno,Matthias Eberl,Adrian Hayday +12 more
TL;DR: Zoledronate + IL-2 represents a novel, safe, and feasible approach to induce immunologic and clinical responses in patients with metastatic carcinomas, potentially providing a substantially increased window for specific approaches to be administered.
Journal ArticleDOI
CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA
Alice Conigliaro,Viviana Costa,Alessia Lo Dico,Laura Saieva,Simona Buccheri,Francesco Dieli,Mauro Manno,Samuele Raccosta,Carmine Mancone,Marco Tripodi,Giacomo De Leo,Riccardo Alessandro,Riccardo Alessandro +12 more
TL;DR: A new exosome-mediated mechanism by which CSC-like CD90+ cells could influence their tumor microenvironment by promoting angiogenic phenotype and cell-to-cell adhesion is indicated.
Journal ArticleDOI
In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Serena Meraviglia,Matthias Eberl,David Vermijlen,Matilde Todaro,Simona Buccheri,Giuseppe Cicero,C. La Mendola,Giuliana Guggino,M. D'Asaro,Valentina Orlando,Francesco Scarpa,Andrew Roberts,Nadia Caccamo,Giorgio Stassi,Francesco Dieli,Adrian Hayday +15 more
TL;DR: The data emphasize the strong linkage of Vγ9Vδ2 T cell status to reduced carcinoma progression, and suggest that zoledronate plus low‐dose IL‐2 offers a novel, safe and feasible approach to enhance this in a subset of treatment‐refractory patients with advanced breast cancer.
Journal ArticleDOI
Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies
Concetta Conticello,Daniela Martinetti,Luana Adamo,Simona Buccheri,Raffaella Giuffrida,Nunziatina Laura Parrinello,Laura Lombardo,Gabriele Anastasi,Gabriella Amato,Maide Cavalli,Annalisa Chiarenza,Ruggero De Maria,Rosario Giustolisi,Massimo Gulisano,Francesco Di Raimondo +14 more
TL;DR: It is shown that multiple myeloma cell lines and primary cells from newly diagnosed and relapsed/resistant patients affected by MM, acute myeloid and lymphoblastic leukemia are significantly sensitive to DSF alone and in combination with copper, and a critical role of ROS is indicated.
Journal ArticleDOI
Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism.
Daniele Simoni,Nicola Gebbia,Francesco Paolo Invidiata,Marco Eleopra,Paolo Marchetti,Riccardo Rondanin,Riccardo Baruchello,Stefano Provera,Carla Marchioro,Manlio Tolomeo,L. Marinelli,Vittorio Limongelli,Ettore Novellino,Aaron Kwaasi,James E. Dunford,Simona Buccheri,Nadia Caccamo,Francesco Dieli +17 more
TL;DR: A small series of aminobisphosphonates (N-BPs) structurally related to zoledronic acid was synthesized with the aim of improving activity toward activation of human gammadelta T cells and in turn their in vivo antitumor activity as discussed by the authors.